[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643751":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":26,"locations":36,"responsibleParty":50,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":25,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":75,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Phenotype-Guided Vasoactive Protocol","EXPERIMENTAL","Recipients undergo intraoperative circulation phenotyping using pulse contour monitoring and fluid responsiveness testing. Vasoactive support is assigned according to phenotype: vasopressin infusion for Hyperdynamic physiology, norepinephrine infusion for Mixed Physiology, calcium chloride and\u002For low-dose dopamine for Poor Contractility, and fluid-guided support for Normal physiology.",[13],"Drug: Phenotype-Guided Vasoactive Management",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Phenotype-Guided Vasoactive Management","Recipients undergo intraoperative circulation phenotyping using pulse contour monitoring and flow-pressure coupling testing. Vasoactive support is assigned according to phenotype: vasopressin infusion for Hyperdynamic physiology, norepinephrine infusion for Mixed Physiology, calcium chloride and\u002For low-dose dopamine for Poor Contractility, and fluid-guided support for Normal physiology.",[9],[21,22,23,24],"Norepinephrine","Calcium Chloride","Dopamine","Vasopressin",null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Jennifer L Cutler, M.D.","CONTACT","310-497-4541","jennifer.cutler@cshs.org",{"name":33,"role":29,"phone":34,"phoneExt":25,"email":35},"Leon Wang, M.D.","203-464-8236","leon.wang@cshs.org",[37],{"facility":38,"status":25,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":25},"Cedars Sinai Medical Center","Los Angeles","California","90048","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-118.24368,34.05223,{"lat":48,"lon":47},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Jennifer Cutler","PI","100643751","phase-4-phenotype-guided-vasoactive-medication-during-kidney-transplantation-100643751",false,"NCT07633600","Phenotype Guided Vasoactive Medication During Kidney Transplantation","Intraoperative Circulation Phenotyping to Guide Vasoactive Medication in Kidney Transplant Recipients","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing kidney transplantation at Cedars-Sinai Medical Center\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Patients unable to provide informed consent\n* Patients with contraindications to protocol vasoactive medications, as determined by the treating anesthesiologist\n* Patients in whom required intraoperative monitoring cannot be performed","ALL","18 Years",{"count":64,"type":65},255,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The goal of this clinical trial is to learn if vasopressin improves the body's response to intravenous fluids during kidney transplantation in patients who have relaxed blood vessels. Researchers will compare the results of vasopressin to those who received calcium chloride.",[71,72],"Kidney Transplant","Fluid Management",[74,71],"Vasoactive Management","NOT_YET_RECRUITING","2026-06-04",{"date":78,"type":79},"2026-06-08","ACTUAL",{"date":81,"type":65},"2026-06-01",{"date":83,"type":65},"2027-12-01",{"name":52,"class":6},1]